Medical isotope developer IsoRay Medical received funding of $5 million through the issuance of 2 million shares of common stock at $2.50 per share and warrants to purchase 2.2 million shares of its common stock at $3 per share.
The Richland, WA, company produces cesium-131 brachytherapy seeds to treat prostate and other cancers.
By AuntMinnie.com staff writers
August 18, 2006
Related Reading
IsoRay begins cesium-131 production testing
IsoRay forecasts record seed orders, June 20, 2006
IsoRay names Hunt as controller, April 19, 2006
IsoRay adds medical advisor, February 1, 2006
IsoRay, IBt notch technology agreement, January 3, 2006
Copyright © 2006 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
